Navigation Links
Warburg Pincus Acquires 5.4% of WuXi PharmaTech's Outstanding Ordinary Shares from United Overseas Bank
Date:7/14/2008

SHANGHAI, China, July 14 /Xinhua-PRNewswire/ -- WuXi PharmaTech (NYSE: WX), a leading pharmaceutical, biotechnology and medical device research and development outsourcing company with operations in China and the United States, today announced that Warburg Pincus, the global private equity firm, has acquired 5.4% of its outstanding ordinary shares from affiliates of United Overseas Bank.

(Logo: http://www.newscom.com/cgi-bin/prnh/20040705/CNM002LOGO )

At the closing of the transaction on July 2, 2008, affiliates of United Overseas Bank (UOB), one of the early venture investors of WuXi PharmaTech, sold to Warburg Pincus a total of 26,808,496 ordinary shares, equivalent to 3,351,062 American Depositary Shares. A beneficial ownership statement Schedule 13D with respect to this acquisition was filed with the Securities and Exchange Commission.

''I am very delighted that Warburg Pincus has decided to invest in WuXi. As a premier global private equity firm with tremendous experience in the life science industry, Warburg Pincus not only will strengthen our investor base, but more importantly we believe that it will provide strategic and business assistance to us,'' commented Dr. Ge Li, Chairman and CEO of WuXi PharmaTech.

''We are pleased to become a shareholder of WuXi PharmaTech which is a clear leader in the rapidly growing drug and medical device outsourcing industry. WuXi has an impressive track record of growth and a distinguished reputation for customer service,'' said Mr. Stewart Hen, Managing Director of Warburg Pincus based in New York. Added Mr. Dai Feng, Principal of Warburg Pincus based in China, ''With our global expertise in healthcare and our deep understanding of the off-shore operating environment, we hope to assist WuXi in achieving its strategic and financial goals.''

About WuXi PharmaTech

Established in December 2000, WuX
'/>"/>

SOURCE WuXi PharmaTech (Cayman) Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. Bioniche Pharma Acquires Baxters ENLON(R) and ENLON-PLUS(R)
2. Neogen Acquires Product Line From DuPont Animal Health Solutions
3. Decision Resources, Inc. Acquires Manhattan Research
4. Fontus Pharmaceuticals Acquires Nephrology and Endocrinology Drug from Roche Laboratories Inc.
5. Miltenyi Biotec GmbH Acquires Medic Tools AG
6. Pacific Biosciences Acquires Single Molecule Sequencing Technology from LI-COR Biosciences
7. Touch Bionics acquires LIVINGSKIN
8. Beckman Coulter Acquires Rights to Hepatitis C Virus
9. China Yingxia International, Inc. Acquires Grocery Chain and Online Distribution Network
10. China Sky One Medical, Inc. Acquires Heilongjiang Haina Pharmaceutical Inc.
11. Royalty Pharma Acquires Royalty Interest in RotaTeq(R) from The Childrens Hospital Foundation for $182 Million

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/20/2009)...E, Nov. 20 Dendreon Corp...U.S. Food and Drug Administration (FDA) provided w...Biologics License Application (BLA) for PROVENGE&#...DA has assigned a Prescription Drug User Fee Act (...respond to Dendreon,s amended BLA. Dendreon is se...
(Date:11/20/2009)... METTLER TOLEDO recently announced that a f...imization Using At-Line Particle Characterization&... this webinar, the application of in situ particle...n space and optimize a series of roller compaction... roller compaction forces. , ...
(Date:11/19/2009)..., Nov. 19 Omeros Corpora...nancial results for the third quarter ended Septem... 30, 2009, Omeros reported a net loss of $3.9 mill... of $7.4 million, or $2.54 per share, for the same...er 30, 2009, the Company reported a net loss of $1...
(Date:11/19/2009)...A, Md., Nov. 19 Spherix ...technology for diabetes therapy, and a provider of...ood, supplement, biotechnology and pharmaceutical ...s Annual Meeting of Shareholders. ,, At the mee...: SPEX ) elected the following members to the Boa...
Breaking Biology Technology:Dendreon Receives FDA Acknowledgement of Complete Response 2Dendreon Receives FDA Acknowledgement of Complete Response 3Roller Compaction Process Optimization Using At-Line Particle Characterization 2Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 2Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 3Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 4Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 5Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 6Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 7Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 8Spherix Announces Results of Annual Shareholders Meeting 2Spherix Announces Results of Annual Shareholders Meeting 3Spherix Announces Results of Annual Shareholders Meeting 4
...heduled for Thursday, March 27TH AT 5 PM ... 20 ImaRx Therapeutics,Inc. (Nasdaq: IMRX ) toda...ast and conference call on Thursday, March 27, 200...d fourth quarter 2007 financial results., The liv...e website at, http://www.imarx.com and will be ar...
...irstCall/ - Chromos Molecular,Systems Inc. ("Chrom...tered,into a secured, convertible debenture agreem...re to be used to fund expenses associated with the...ocuments and maintaining,the integrity of the rema...erest, at 12% per annum, are due and payable on Ju...
...armAthene,s Status as a Premie...panded Biodefense Pipeline ANNAPOLIS, Md., and TE... biodefense company,specializing in the developmen... against biological and chemical threats, and Avec...iopharmaceuticals, announced,today that the compan...
Other Biology Technology:ImaRx to Report Corporate Updates and 4Q07 Financial Results 2Chromos enters into loan and lending arrangements 2PharmAthene Signs Definitive Agreement to Acquire Biodefense Vaccines Business From Avecia 2PharmAthene Signs Definitive Agreement to Acquire Biodefense Vaccines Business From Avecia 3PharmAthene Signs Definitive Agreement to Acquire Biodefense Vaccines Business From Avecia 4PharmAthene Signs Definitive Agreement to Acquire Biodefense Vaccines Business From Avecia 5PharmAthene Signs Definitive Agreement to Acquire Biodefense Vaccines Business From Avecia 6
(Date:11/19/2009)...ain chemical with an unwieldy name: 4-hydroxybutyr...ed as a date-rape drug. , Now, a team of Ohio a...by which 4-HB is metabolized by the body. "This is...ibson, professor and chair of biological sciences ...of the research team. "It may provide new clues o...
(Date:11/19/2009)... many countries of the world. It is widely used fo...aterials. It also is considered an exemplar plant ...ution, and genome architecture. The authors of the...d the first description of the B73 maize genome to...netics and plant biology. The ten papers consider ...
(Date:11/19/2009)... 19 BIO-key Internationa...reless public safety and finger-based biometric id... Shareholder Meeting held today was adjourned with...t present. ,, (Logo: http://www.newscom.com/cg...ressive 99.3% of the 35 million votes cast voted i...
Breaking Biology News(10 mins):Researchers begin to decipher metabolism of sexual assault drug 2PLoS Genetics 2009 maize genome collection 2PLoS Genetics 2009 maize genome collection 3PLoS Genetics 2009 maize genome collection 4BIO-key(R) Provides Update to Special Shareholder Meeting 2BIO-key(R) Provides Update to Special Shareholder Meeting 3Photos 3A New Yoplait 28R 29 YoPlus 28TM 29 Light A Delicious Way to Regulate Digestive Health With Fewer Calories 57506 1Photos 3A New Yoplait 28R 29 YoPlus 28TM 29 Light A Delicious Way to Regulate Digestive Health With Fewer Calories 57506 2Photos 3A New Yoplait 28R 29 YoPlus 28TM 29 Light A Delicious Way to Regulate Digestive Health With Fewer Calories 57506 3Clinical Trials Move to Emerging Regions Heighten Need for Local Risk Consulting 3A Aon Global Risk Map 14121 1Clinical Trials Move to Emerging Regions Heighten Need for Local Risk Consulting 3A Aon Global Risk Map 14121 2Clinical Trials Move to Emerging Regions Heighten Need for Local Risk Consulting 3A Aon Global Risk Map 14121 3Clinical Trials Move to Emerging Regions Heighten Need for Local Risk Consulting 3A Aon Global Risk Map 14121 4Clinical Trials Move to Emerging Regions Heighten Need for Local Risk Consulting 3A Aon Global Risk Map 14121 5Damon Runyon 5K Run Walk at Yankee Stadium to Benefit Cancer Research 57502 1Damon Runyon 5K Run Walk at Yankee Stadium to Benefit Cancer Research 57502 2Damon Runyon 5K Run Walk at Yankee Stadium to Benefit Cancer Research 57502 3Damon Runyon 5K Run Walk at Yankee Stadium to Benefit Cancer Research 57502 4
...rves have been jangled by a baby,s howl or who hav...n knows, nature has evolved sensory systems to be ...ion in neurobiology is how neurons tune the streng...to such inputs. , Neuronal circuitry consists of a...ng bursts of neurotransmitters at targets on recei...
...scovered that a group of important immune system c...tish superspy James Bond: the cells receive a "lic...t attacks on enemies. , This licensing process app...ll erroneously direct their firepower at the body,...ton University School of Medicine in St. Louis. Th...
...r, at least not the size of the eyespots on a male...r potential mates. , Instead, females are attract...lectivity of the pupils, the white circles at the ... University at Buffalo biologists. , The research,... of the Royal Society B: Biological Sciences, over...
Other Biology News:Grasshopper love songs give insight into sensory tuning 2'License to kill' enables powerful immune attack cells in mice 2'License to kill' enables powerful immune attack cells in mice 3Female butterflies go for sparkle -- not size -- when choosing to mate 2Female butterflies go for sparkle -- not size -- when choosing to mate 3
Oligonucleotides from Thermo Scientific
Mouse Anti-Human QPCT Monoclonal Antibody, Unconjugated, Clone 4E11 from Novus Biologicals
LS Columns from Miltenyi Biotec
Corning ultragaps Coated Slides,Bar-Coded from Sigma-Aldrich
Biology Products: